Clinical Trials Directory

Trials / Unknown

UnknownNCT05630898

Congenital Cytomegalovirus: Prevalence in Buenos Aires City (cCMV Prevalence)

Congenital Cytomegalovirus: Prevalence in Buenos Aires City

Status
Unknown
Phase
Study type
Observational
Enrollment
3,000 (estimated)
Sponsor
Hospital de Niños R. Gutierrez de Buenos Aires · Academic / Other
Sex
All
Age
1 Day – 21 Days
Healthy volunteers
Not accepted

Summary

The goal of this observational study is to recognise the prevalnce of congenital cytomegalovirus (cCMV) and to follow up positive babies until 12 months The main questions it aims to answer are: pevalence of cCMV, cCMV clinicals outcomes during the first year of life. Participants will be screened with a salive swab for CMV DNA. Babies with positive results will be follow up for one year.

Detailed description

Cytomegalovirus (CMV) is a frequent cause of congenital infection and a leading nongenetic cause of sensorineural hearing loss. In most infants with congenital CMV infection, clinical abnormalities do not manifest at birth; rather, the infection is asymptomatic. However, sensorineural hearing loss eventually develops in approximately 10 to 15% of CMV positive children. The prevalence of congenital cytomegalovirus has been reported as 0·2% to 2·0% (average of 0·64%). There is not any publication of the prevalence of cCMV in Buenos Aires City. We aim the study to find the prevalence in this population Screening of newborns for CMV infection permit early identification of at-risk congenitally infected infants for purposes of targeted monitoring and intervention during critical stages of speech and language development. Testing saliva via DNA detection of the virus through polymerase chain reaction testing (PCR) or rapid culture is shown to have a high sensitivity (\>97%) and specificity (99%) for detecting congenital CMV infection. Our objective is to describe the prevalence of cCMV using saliva specimens for PCR detection. Secondary objectives includes describing prevalence of neurosensorial hearing loss and visual impairments during 1 year follow up.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTCMV PCRSaliva CMV PCR

Timeline

Start date
2023-04-01
Primary completion
2024-09-30
Completion
2024-12-30
First posted
2022-11-30
Last updated
2022-11-30

Locations

3 sites across 1 country: Argentina

Source: ClinicalTrials.gov record NCT05630898. Inclusion in this directory is not an endorsement.